Innoviva (INVA) Non-Current Debt (2010 - 2026)
Innoviva's (INVA) quarterly Non-Current Debt came in at $258.1 million in Q1 2026, up 0.56% YoY from $256.7 million in Q1 2025, and little changed on a QoQ basis from $257.7 million in Q4 2025.
Innoviva (INVA) Non-Current Debt (2010 - 2026) Analysis & Trends
Innoviva (INVA) has 14 years of Non-Current Debt data on file, last reported at $258.1 million in Q1 2026.
- Quarterly Non-Current Debt rose 0.56% year-over-year to $258.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $258.1 million (up 0.56% YoY) and the FY2025 annual result came in at $257.7 million, up 0.55% from the prior year.
- Non-Current Debt steadied at $258.1 million in Q1 2026, from $257.7 million in the prior quarter.
- In the past five years, Non-Current Debt ranged from a high of $447.3 million in Q2 2024 to a low of $256.0 million in Q3 2024.
- A 5-year average of $357.5 million and a median of $443.7 million in 2022 frame the typical range for Non-Current Debt.
- Annual changes were most pronounced in 2022 — Non-Current Debt climbed 13.1% — and 2024, when it slumped 42.57%.
- Tracing INVA's Non-Current Debt over 5 years: stood at $444.2 million in 2022, then climbed by 0.46% to $446.2 million in 2023, then plunged by 42.56% to $256.3 million in 2024, then increased by 0.55% to $257.7 million in 2025, then gained by 0.14% to $258.1 million in 2026.
- The last three Non-Current Debt figures came in at $258.1 million (Q1 2026), $257.7 million (Q4 2025), and $257.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Innoviva | 1.54 Bn | 968.79 Mn | 90.62 Mn | 258.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 258.45 Mn |
| Mar 31, 2026 | 258.10 Mn |
| Dec 31, 2025 | 257.73 Mn |
| Sep 30, 2025 | 257.38 Mn |
| Jun 30, 2025 | 257.02 Mn |
| Mar 31, 2025 | 256.67 Mn |
| Dec 31, 2024 | 256.32 Mn |
| Sep 30, 2024 | 255.97 Mn |
| Jun 30, 2024 | 447.28 Mn |
| Mar 31, 2024 | 446.76 Mn |
| Dec 31, 2023 | 446.23 Mn |
| Sep 30, 2023 | 445.72 Mn |
| Jun 30, 2023 | 445.20 Mn |
| Mar 31, 2023 | 444.69 Mn |
| Dec 31, 2022 | 444.18 Mn |
| Sep 30, 2022 | 443.68 Mn |
| Dec 31, 2021 | 394.65 Mn |
| Sep 30, 2021 | 392.30 Mn |
| Jun 30, 2021 | 389.99 Mn |
| Mar 31, 2021 | 387.73 Mn |